Literature DB >> 30665572

A distinct bone phenotype in ADPKD patients with end-stage renal disease.

Pieter Evenepoel1, Kathleen Claes2, Etienne Cavalier3, Bjorn Meijers2, Peter Stenvinkel4, Geert Behets5, Magdalena Jankowska6, Patrick D'Haese5, Bert Bammens2.   

Abstract

Autosomal dominant polycystic kidney disease (ADPKD) is among the most common hereditary nephropathies. Low bone turnover osteopenia has been reported in mice with conditional deletion of the PKD1 and PKD2 genes in osteoblasts, and preliminary clinical data also suggest suppressed bone turnover in patients with ADPKD. The present study compared the bone phenotype between patients with end stage renal disease (ESRD) due to ADPKD and controls with ESRD due to other causes. Laboratory parameters of bone mineral metabolism (fibroblast growth factor 23 and sclerostin), bone turnover markers (bone alkaline phosphatase, tartrate-resistant acid phosphatase 5b) and bone mineral density (BMD, by dual energy x-ray absorptiometry, DXA) were assessed in 518 patients with ESRD, including 99 with ADPKD. Bone histomorphometry data were available in 71 patients, including 10 with ADPKD. Circulating levels of bone alkaline phosphatase were significantly lower in patients with ADPKD (17.4 vs 22.6 ng/mL), as were histomorphometric parameters of bone formation. Associations between ADPKD and parameters of bone formation persisted after adjustment for classical determinants including parathyroid hormone, age, and sex. BMD was higher in skeletal sites rich in cortical bone in patients with ADPKD compared to non-ADPKD patients (Z-score midshaft radius -0.04 vs -0.14; femoral neck -0.72 vs -1.02). Circulating sclerostin levels were significantly higher in ADPKD patients (2.20 vs 1.84 ng/L). In conclusion, patients with ESRD due to ADPKD present a distinct bone and mineral phenotype, characterized by suppressed bone turnover, better preserved cortical BMD, and high sclerostin levels.
Copyright © 2019 International Society of Nephrology. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  ADPKD; bone; mineral metabolism

Year:  2019        PMID: 30665572     DOI: 10.1016/j.kint.2018.09.018

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  7 in total

Review 1.  Traditional and Non-traditional Risk Factors for Osteoporosis in CKD.

Authors:  Hanne Skou Jørgensen; Karel David; Syazrah Salam; Pieter Evenepoel
Journal:  Calcif Tissue Int       Date:  2021-02-14       Impact factor: 4.333

Review 2.  Peripheral Blood Mononuclear Cells (PBMCs) to Dissect the Underlying Mechanisms of Bone Disease in Chronic Kidney Disease and Rare Renal Diseases.

Authors:  Irma Machuca-Gayet; Justine Bacchetta; Julie Bernardor; Candide Alioli; Marie-Noelle Meaux; Olivier Peyruchaud
Journal:  Curr Osteoporos Rep       Date:  2021-11-13       Impact factor: 5.096

Review 3.  Bone Disease in Nephropathic Cystinosis: Beyond Renal Osteodystrophy.

Authors:  Irma Machuca-Gayet; Thomas Quinaux; Aurélia Bertholet-Thomas; Ségolène Gaillard; Débora Claramunt-Taberner; Cécile Acquaviva-Bourdain; Justine Bacchetta
Journal:  Int J Mol Sci       Date:  2020-04-28       Impact factor: 5.923

4.  Characterization of Primary Cilia in Osteoblasts Isolated From Patients With ADPKD and CKD.

Authors:  Renata C Pereira; Berenice Y Gitomer; Michel Chonchol; Peter C Harris; Kathleen J Noche; Isidro B Salusky; Lauren V Albrecht
Journal:  JBMR Plus       Date:  2021-02-23

Review 5.  Utility of Trabecular Bone Score (TBS) in Bone Quality and Fracture Risk Assessment in Patients on Maintenance Dialysis.

Authors:  Catalina Poiana; Roxana Dusceac; Dan Alexandru Niculescu
Journal:  Front Med (Lausanne)       Date:  2022-01-20

6.  Bone turnover correlates with bone quantity but not bone microarchitecture in chronic hemodialysis.

Authors:  Roxana Dusceac; Dan Alexandru Niculescu; Ramona Dobre; Madalina Cristina Sorohan; Andra Caragheorgheopol; Catalin Tacu; Cristiana David; Catalina Poiana
Journal:  J Bone Miner Metab       Date:  2020-03-06       Impact factor: 2.626

7.  Mineral bone disease in autosomal dominant polycystic kidney disease.

Authors:  Berenice Gitomer; Renata Pereira; Isidro B Salusky; Jason W Stoneback; Tamara Isakova; Xuan Cai; Lorien S Dalrymple; Norma Ofsthun; Zhiying You; Harmut H Malluche; Franklin Maddux; Diana George; Vicente Torres; Arlene Chapman; Theodore I Steinman; Myles Wolf; Michel Chonchol
Journal:  Kidney Int       Date:  2020-09-11       Impact factor: 10.612

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.